ScreenerHero
HLSHLS Therapeutics Inc.
TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · hlstherapeutics.com
3.800CAD-3.55%Mkt Cap: 88.76M $P/E: —

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and inter…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap88.76M $
Enterprise Value109.28M $
Revenue (TTM)40.96M $
Gross Profit33.08M $
Net Income (TTM)-9.05M $
Revenue/Share1.309 USD
Last Price3.800 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees85
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-40.75
PEG—
EV/EBITDA8.82
EV/Revenue2.67
P/S2.17
P/B1.61
EPS (TTM)-0.37
EPS (Forward)-0.10
52W Range
0.001066% of range5.765
52W High5.765 CAD
52W Low0.0010 CAD
Profitability
Gross Margin81.83%
Oper. Margin-7.88%
EBITDA Margin30.24%
Profit Margin-22.40%
ROE-20.16%
ROA-9.04%
Growth
Revenue Growth3.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF12.48M $
CapEx (TTM)1.24M $
FCF Margin36.47%
FCF Yield16.83%
Net Debt20.52M $
Net Debt/EBITDA1.66
Balance Sheet
Debt/Equity0.81
Current Ratio1.05
Quick Ratio0.76
Book Value/Sh2.450 CAD
Cash/Share0.4440 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield1.73%
Payout Ratio0.00%
Ex-Div DateApr 27, 2023
Pay DateJun 15, 2023
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.264 CAD
Upside (mean)+91.1%
Target Range4.386 CAD – 11.85 CAD
CAD4.386+91.1% to meanCAD11.85
# Analysts4
Ownership
Shares Out.30.94M
Float19.27M
Insiders0.54%
Institutions44.45%
Short Interest
Short Ratio0.4d
Short % Out.0.03%
Shares Short1.15K
Short (prev mo.)302.31K
Technical
SMA 504.182 (-9.1%)
SMA 2004.540 (-16.3%)
Beta0.86
S&P 52W Chg18.16%
Avg Vol (30d)27.66K
Avg Vol (10d)125.23K
Technical Indicators
RSI (14)41.8
MACD-0.0954
MACD Signal-0.0841
MACD Hist.-0.0113
BB Upper4.340 CAD
BB Middle4.063 CAD
BB Lower3.786 CAD
BB Width13.63%
ATR (14)0.1731 CAD
Vol Ratio (20d)1.74x